.svg){kind=small}
The study comprised a total of 232 randomised males and it measured, as its primary endpoint, improvement in the erectile function ("EF") domain score of the International Index of Erectile Function ("IIEF"), the scoring system used for the approval of PDE5 inhibitors such as Viagra®. The study was of a placebo-controlled, double blind, home use, crossover design.View news article
.avif)
Latest news
How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)
February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read moreEvents
Clinical Trials Innovation Programme
10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event
